ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 214,35
0,33%
Dow Jones
39 408,86
0,05%
DAX
18 756,86
0,41%
Brent Oil
83,405
-0,65%
Bitcoin
60 826,45
-3,52%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. SQZ Biotechnologies Company (SQZ)

  7. SQZ Biotechnologies Company (SQZ) Actualités

SQZ

SQZ Biotechnologies (SQZ)

SQZ Biotechnologies Company
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:SQZ
DateHeureSourceTitreSymboleSociété
06/05/202412h25GlobeNewswire Inc.Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd WiderNYSE:SQZSQZ Biotechnologies Company
23/01/202422h31Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNYSE:SQZSQZ Biotechnologies Company
22/12/202323h18Edgar (US Regulatory)Form 8-K - Current reportNYSE:SQZSQZ Biotechnologies Company
08/11/202322h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:SQZSQZ Biotechnologies Company
15/06/202322h47Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:SQZSQZ Biotechnologies Company
15/06/202322h38Edgar (US Regulatory)Current Report Filing (8-k)NYSE:SQZSQZ Biotechnologies Company
15/06/202322h30Business WireSQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock SplitNYSE:SQZSQZ Biotechnologies Company
10/05/202322h45Business WireSQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio UpdatesNYSE:SQZSQZ Biotechnologies Company
10/05/202322h35Edgar (US Regulatory)Quarterly Report (10-q)NYSE:SQZSQZ Biotechnologies Company
05/05/202322h32Edgar (US Regulatory)Annual Report to Security Holders (ars)NYSE:SQZSQZ Biotechnologies Company
26/04/202322h32Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NYSE:SQZSQZ Biotechnologies Company
26/04/202322h31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NYSE:SQZSQZ Biotechnologies Company
10/04/202322h32Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NYSE:SQZSQZ Biotechnologies Company
22/03/202321h50Business WireSQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical TrialNYSE:SQZSQZ Biotechnologies Company
22/03/202321h45Business WireSQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio UpdatesNYSE:SQZSQZ Biotechnologies Company
14/02/202320h25Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:SQZSQZ Biotechnologies Company
18/01/202322h30Business WireSQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock ExchangeNYSE:SQZSQZ Biotechnologies Company
06/12/202217h55TipRanksSQZ Biotechnologies (SQZ) Gets a Hold from H.C. WainwrightNYSE:SQZSQZ Biotechnologies Company
06/12/202214h55TipRanksSQZ Biotechnologies (SQZ) Receives a Buy from Brookline Capital MarketsNYSE:SQZSQZ Biotechnologies Company
06/12/202212h45Business WireSQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology CongressNYSE:SQZSQZ Biotechnologies Company
02/12/202212h15TipRanksSQZ Biotechnologies (SQZ) was downgraded to a Hold Rating at H.C. WainwrightNYSE:SQZSQZ Biotechnologies Company
01/12/202213h55TipRanksChardan Capital Sticks to Their Buy Rating for SQZ Biotechnologies (SQZ)NYSE:SQZSQZ Biotechnologies Company
30/11/202222h30Business WireSQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive OfficerNYSE:SQZSQZ Biotechnologies Company
10/11/202215h00Business WireSQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual MeetingNYSE:SQZSQZ Biotechnologies Company
10/11/202212h17TipRanksSQZ Biotechnologies (SQZ) Receives a Buy from H.C. WainwrightNYSE:SQZSQZ Biotechnologies Company
10/11/202201h55TipRanksBrookline Capital Markets Reaffirms Their Buy Rating on SQZ Biotechnologies (SQZ)NYSE:SQZSQZ Biotechnologies Company
09/11/202222h30Business WireSQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio UpdatesNYSE:SQZSQZ Biotechnologies Company
03/10/202212h45Business WireSQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived ImmunotherapyNYSE:SQZSQZ Biotechnologies Company
12/09/202215h15TipRanksBrookline Capital Markets Keeps Their Buy Rating on SQZ Biotechnologies (SQZ)NYSE:SQZSQZ Biotechnologies Company
12/09/202212h00Business WireSQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell TherapiesNYSE:SQZSQZ Biotechnologies Company
 Showing the most relevant articles for your search:NYSE:SQZ

Dernières Valeurs Consultées

NYSE
JPM
JP Morgan Chase
EU
AF
Air FranceKLM
EU
LR
Legrand
SPI
SP500
S&P 500
FTSE
UKX
FTSE 100
EU
PX1
CAC 40
COIN
BTCUSD
Bitcoin
EU
RI
Pernod Ricard
EU
ACA
Credit Agricole
NYSE
MCD
McDonalds
EU
ML
Michelin
EU
CAP
Capgemini
EU
GLE
Societe Generale
EU
CS
Axa
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés